Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Enterprise Value (2020 - 2025)

Historic Enterprise Value for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to -$48.7 million.

  • Mereo BioPharma's Enterprise Value rose 3951.96% to -$48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.7 million, marking a year-over-year increase of 3951.96%. This contributed to the annual value of -$69.8 million for FY2024, which is 2156.18% down from last year.
  • As of Q3 2025, Mereo BioPharma's Enterprise Value stood at -$48.7 million, which was up 3951.96% from -$56.1 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma's Enterprise Value registered a high of -$32.8 million during Q2 2021, and its lowest value of -$127.1 million during Q4 2021.
  • Over the past 5 years, Mereo BioPharma's median Enterprise Value value was -$65.3 million (recorded in 2022), while the average stood at -$71.5 million.
  • As far as peak fluctuations go, Mereo BioPharma's Enterprise Value crashed by 31017.55% in 2021, and later surged by 4636.07% in 2022.
  • Over the past 5 years, Mereo BioPharma's Enterprise Value (Quarter) stood at -$127.1 million in 2021, then skyrocketed by 46.36% to -$68.2 million in 2022, then increased by 15.78% to -$57.4 million in 2023, then decreased by 21.56% to -$69.8 million in 2024, then surged by 30.23% to -$48.7 million in 2025.
  • Its last three reported values are -$48.7 million in Q3 2025, -$56.1 million for Q2 2025, and -$62.5 million during Q1 2025.